Blaise Coleman - Endo International President
President
Mr. Blaise Coleman serves as Chief Financial Officer, Executive Vice President of the Company. Mr. Coleman was serving as Endo Interim Chief Financial Officer since November 22, 2016. Mr. Coleman joined Endo in January 2015 as Vice President of Corporationrationrate Financial Planning Analysis and was promoted to Senior Vice President of Global Finance Operations in November 2015. Prior to joining Endo, Mr. Coleman held a number of finance leadership roles with AstraZeneca, a global biopharmaceutical company, latterly as the Chief Financial Officer of the AstraZenecaBristolMyers Squibb US Diabetes Alliance from January 2013 until January 2015. Prior to this, he was the Head of Finance for the AstraZeneca Global Medicines Development organization based in Mlndal, Sweden from September 2011 to January 2013. Mr. Coleman joined AstraZeneca as Senior Director Commercial Finance for the US Cardiovascular Business in November 2007. He joined AstraZeneca from Centocor, a wholly owned subsidiary of Johnson Johnson, where he held positions in the respective Licenses Acquisitions and Commercial Finance organizations. Mr. Colemans move to Centocor in early 2003 followed 7 years experience with the global public accounting firm, PricewaterhouseCoopers LLP. He is a Certified Public Accountant since 2016.
Age | 43 |
Tenure | 8 years |
Professional Marks | MBA |
Phone | 353 1 268 2000 |
Web | https://www.endo.com |
Endo International Management Efficiency
The company has return on total asset (ROA) of 5.11 % which means that it generated a profit of $5.11 on every $100 spent on assets. This is normal as compared to the sector avarege. Endo International's management efficiency ratios could be used to measure how well Endo International manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 8.13 B in liabilities with Debt to Equity (D/E) ratio of 1.98, which is about average as compared to similar companies. Endo International PLC has a current ratio of 1.77, which is within standard range for the sector. Debt can assist Endo International until it has trouble settling it off, either with new capital or with free cash flow. So, Endo International's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Endo International PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Endo to invest in growth at high rates of return. When we think about Endo International's use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | PRESIDENT Age | ||
Robert Katz | Jabil Circuit | 61 | |
Jean Philibert | Analog Devices | 56 | |
Margaret Seif | Analog Devices | 56 | |
Paul Korner | Ardelyx | 50 | |
Elizabeth Grammer | Ardelyx | 60 | |
Bryan Shaw | Ardelyx | 61 | |
Steven Pietkiewicz | Analog Devices | 58 | |
Rick Hess | Analog Devices | 61 | |
Yusuf Jamal | Analog Devices | 40 | |
Courteny Ryan | Jabil Circuit | 47 | |
Charles Mathis | ScanSource | 55 | |
Dennis Ackerman | Bel Fuse A | 61 | |
Reginal Seeto | Ardelyx | 44 | |
Peter III | Bel Fuse A | 54 | |
Peter Bittner | Bel Fuse A | 48 | |
Daryn Smith | Jabil Circuit | 50 | |
Sergio Cadavid | Jabil Circuit | 62 | |
Bruce Johnson | Jabil Circuit | 64 | |
Tetsuya Tsurumaru | Renesas Electronics | 63 | |
William Matson | Analog Devices | 54 | |
Michael Hannawald | Renesas Electronics | N/A |
Management Performance
Return On Equity | 0.007 | |||
Return On Asset | 5.11 |
Endo International PLC Leadership Team
Elected by the shareholders, the Endo International's board of directors comprises two types of representatives: Endo International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Endo. The board's role is to monitor Endo International's management team and ensure that shareholders' interests are well served. Endo International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Endo International's outside directors are responsible for providing unbiased perspectives on the board's policies.
Carrie Nichol, Chief Accounting Officer, Vice President Controller | ||
William Spengler, Director | ||
Arthur Higgins, Independent Director | ||
Brian Lortie, President U.S. Branded Pharmaceuticals | ||
Donald DeGolyer, Special Advisor to the CEO | ||
William Montague, Director | ||
Michael Hyatt, Director | ||
Douglas Ingram, Director | ||
Antonio Pera, President - Par Pharmaceutical | ||
Domenic Ciarico, Executive Vice President Chief Commercial Officer - Sterile and Generics | ||
Roger Kimmel, Chairman of the Board | ||
Susan Hall, Chief Scientific Officer, Global Head of RandD and Quality and Executive VP | ||
Sharad Mansukani, Director | ||
Suketu Upadhyay, CFO and Executive VP | ||
Nancy Hutson, Independent Director | ||
Todd Sisitsky, Director | ||
Patrick Barry, Executive Vice President and Chief Commercial Officer | ||
Shane Cooke, Independent Director | ||
Craig Paterson, Chief Medical Officer | ||
Daniel Rudio, Senior Vice President Chief Accounting Officer, Controller | ||
Camille Farhat, President of American Medical Systems, Inc | ||
Paul Campanelli, President CEO, Director | ||
Jill Smith, Director | ||
Rajiv Silva, CEO and President and Director | ||
Nina Goworek, Senior Director, Investor Relations | ||
Blaise Coleman, Senior Vice President of Global Finance Operations and Interim CFO | ||
Terrance Coughlin, COO, Executive Vice President | ||
Matthew Maletta, Executive Vice President Chief Legal Officer |
Endo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Endo International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.007 | |||
Return On Asset | 5.11 | |||
Profit Margin | (24.82) % | |||
Operating Margin | 24.70 % | |||
Current Valuation | 6.84 B | |||
Shares Outstanding | 233.67 M | |||
Shares Owned By Insiders | 0.79 % | |||
Shares Owned By Institutions | 83.64 % | |||
Number Of Shares Shorted | 41.45 M | |||
Price To Earning | 0.37 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Endo International in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Endo International's short interest history, or implied volatility extrapolated from Endo International options trading.
Pair Trading with Endo International
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Endo International position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Endo International will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Sempra Energy could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sempra Energy when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sempra Energy - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sempra Energy to buy it.
The correlation of Sempra Energy is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sempra Energy moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sempra Energy moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sempra Energy can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Endo International PLC information on this page should be used as a complementary analysis to other Endo International's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Endo Stock
If you are still planning to invest in Endo International PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Endo International's history and understand the potential risks before investing.
CEOs Directory Screen CEOs from public companies around the world | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |